Genmab A/S (NASDAQ:GMAB) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Shares of Genmab A/S (NASDAQ:GMAB - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the thirteen research firms that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation, eight have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $39.17.

A number of research firms have recently issued reports on GMAB. Leerink Partners upgraded shares of Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 price objective on the stock in a report on Thursday, February 13th. BNP Paribas raised Genmab A/S from a "strong sell" rating to a "hold" rating in a research report on Tuesday, February 11th. Leerink Partnrs raised Genmab A/S from a "hold" rating to a "strong-buy" rating in a research report on Thursday, February 13th. Truist Financial cut their price objective on Genmab A/S from $50.00 to $45.00 and set a "buy" rating for the company in a report on Tuesday, March 11th. Finally, William Blair upgraded shares of Genmab A/S from a "market perform" rating to an "outperform" rating in a report on Tuesday, March 11th.

Hedge Funds Weigh In On Genmab A/S

Institutional investors and hedge funds have recently modified their holdings of the stock. Scientech Research LLC lifted its stake in shares of Genmab A/S by 209.5% during the 1st quarter. Scientech Research LLC now owns 34,611 shares of the company's stock worth $678,000 after buying an additional 23,428 shares during the last quarter. Cubist Systematic Strategies LLC raised its holdings in Genmab A/S by 112.4% in the 1st quarter. Cubist Systematic Strategies LLC now owns 1,258,143 shares of the company's stock valued at $24,634,000 after acquiring an additional 665,893 shares during the period. Graham Capital Management L.P. lifted its position in Genmab A/S by 28.9% during the first quarter. Graham Capital Management L.P. now owns 71,452 shares of the company's stock worth $1,399,000 after acquiring an additional 16,035 shares during the last quarter. Orbis Allan Gray Ltd lifted its position in Genmab A/S by 102.8% during the first quarter. Orbis Allan Gray Ltd now owns 5,710,741 shares of the company's stock worth $111,816,000 after acquiring an additional 2,895,179 shares during the last quarter. Finally, Vident Advisory LLC bought a new stake in shares of Genmab A/S during the first quarter worth approximately $242,000. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Genmab A/S Stock Performance

GMAB stock traded up $0.19 during mid-day trading on Monday, hitting $20.52. 1,536,651 shares of the company were exchanged, compared to its average volume of 1,116,639. Genmab A/S has a 1-year low of $17.24 and a 1-year high of $30.06. The firm's 50 day simple moving average is $19.75 and its 200 day simple moving average is $20.72. The firm has a market cap of $13.16 billion, a P/E ratio of 11.79, a P/E/G ratio of 2.65 and a beta of 1.04.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported $0.31 EPS for the quarter, beating the consensus estimate of $0.23 by $0.08. The business had revenue of $715.00 million for the quarter, compared to analysts' expectations of $5.17 billion. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. On average, equities research analysts predict that Genmab A/S will post 1.45 EPS for the current fiscal year.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.